Cargando…

How artificial intelligence might disrupt diagnostics in hematology in the near future

Artificial intelligence (AI) is about to make itself indispensable in the health care sector. Examples of successful applications or promising approaches range from the application of pattern recognition software to pre-process and analyze digital medical images, to deep learning algorithms for subt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walter, Wencke, Haferlach, Claudia, Nadarajah, Niroshan, Schmidts, Ines, Kühn, Constanze, Kern, Wolfgang, Haferlach, Torsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225509/ https://www.ncbi.nlm.nih.gov/pubmed/34103684 http://dx.doi.org/10.1038/s41388-021-01861-y

Ejemplares similares

Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesis
por: Müller, Heiko, et al.
Publicado: (2022)

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies
por: Stengel, Anna, et al.
Publicado: (2021)

S161: UBA1 NON-M41 VARIANTS ARE MORE AGGRESSIVE THAN UBA1 M41 VARIANTS IN THEIR HEMATOLOGICAL MANIFESTATIONS.
por: Sakuma, Maki, et al.
Publicado: (2023)

Risk prediction in MDS: independent validation of the IPSS-M—ready for routine?
por: Baer, Constance, et al.
Publicado: (2023)

Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations
por: Höllein, Alexander, et al.
Publicado: (2019)

Dark-matter matters: Discriminating subtle blood cancers using the darkest DNA
por: Parida, Laxmi, et al.
Publicado: (2019)

Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies
por: Sakuma, Maki, et al.
Publicado: (2023)

Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia
por: Walter, Wencke, et al.
Publicado: (2021)

P690: IDENTIFICATION OF CLINICALLY RELEVANT VARIANT-LEVEL SEX-BIAS IN SF3B1 K700/K666 AND IDH2 R140/R172
por: Sakuma, Maki, et al.
Publicado: (2023)

The power and potential of integrated diagnostics in acute myeloid leukaemia
por: Haferlach, Torsten, et al.
Publicado: (2019)

“Somatic” and “pathogenic” - is the classification strategy applicable in times of large-scale sequencing?
por: Baer, Constance, et al.
Publicado: (2019)

Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration
por: Cappelli, Luca Vincenzo, et al.
Publicado: (2021)

Complex Landscape of Alternative Splicing in Myeloid Neoplasms
por: Hershberger, Courtney E., et al.
Publicado: (2020)

P533: A FULLY AUTOMATED SUPERVISED AI-BASED CELL CLASSIFIER TO ACCURATELY FLAG PATHOLOGICAL SIGNATURE CELLS IN 28,285 REAL-WORLD BLOOD SMEARS
por: Maier, Christopher, et al.
Publicado: (2023)

The time has come for next-generation sequencing in routine diagnostic workup in hematology
por: Haferlach, Torsten
Publicado: (2021)

P1213: ARTIFICIAL INTELLIGENCE TO PREDICT MEDICAL DIAGNOSIS FROM FLOW CYTOMETRIC RAW DATA IN MATURE B-CELL AND T-CELL NEOPLASMS, AML, ALL, MDS AND MULTIPLE MYELOMA
por: Müller, Martha-Lena, et al.
Publicado: (2023)

Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes
por: Meggendorfer, Manja, et al.
Publicado: (2017)

Correction: How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing
por: Müller, Janine, et al.
Publicado: (2022)

How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing
por: Müller, Janine, et al.
Publicado: (2022)

The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers
por: Haferlach, Torsten, et al.
Publicado: (2007)

Detection of ABL1 kinase domain mutations in therapy-naïve BCR-ABL1-positive acute lymphoblastic leukemia
por: Baer, Constance, et al.
Publicado: (2021)

P814: ANALYSIS OF TP53 ALTERATIONS BY WGS REVEALS BIALLELIC 17P DELETIONS IN MULTIPLE MYELOMA
por: Truger, Marietta, et al.
Publicado: (2023)

Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML
por: Wojtuszkiewicz, Anna, et al.
Publicado: (2021)

Molecular analysis of RAS-RAF tyrosine-kinase signaling pathway alterations in patients with plasma cell myeloma
por: Grossmann, V, et al.
Publicado: (2012)

Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

P707: MUTATIONS IN THE COHESIN GENE STAG2 ARE ASSOCIATED WITH REDUCED INFLAMMATORY GENEEXPRESSION AND AN INCREASE IN HEMATOPOIETIC STEM CELL POPULATIONS IN MYELODYSPLASTICSYNDROME PATIENTS
por: Ashish Bhattacharya, Shubhra, et al.
Publicado: (2023)

SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis
por: Huber, Sandra, et al.
Publicado: (2022)

SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase
por: Huber, Sandra, et al.
Publicado: (2022)

P689: CLASSIFICATION OF MDS AND AML BASED SOLELY ON GENETICS OMITTING BLAST COUNTING – A WAY TO RESOLVE THE DISCREPANCIES BETWEEN CLASSIFICATIONS ACCORDING TO WHO AND ICC?
por: Haferlach, Claudia, et al.
Publicado: (2023)

Comprehensive study on ERG gene expression in normal karyotype acute myeloid leukemia: ERG expression is of limited prognostic value, whereas the accumulation of adverse prognostic markers stepwise worsens the prognosis
por: Weber, S, et al.
Publicado: (2016)

AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics
por: Fuhrmann, Irene, et al.
Publicado: (2022)

MDS subclassification—do we still have to count blasts?
por: Huber, Sandra, et al.
Publicado: (2023)

SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia
por: van der Werf, Inge, et al.
Publicado: (2021)

BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia
por: Weber, S, et al.
Publicado: (2014)

An artificial intelligence‐assisted diagnostic platform for rapid near‐patient hematology
por: Bachar, Neta, et al.
Publicado: (2021)

Frequency and Prognostic Impact of CEBPA Proximal, Distal and Core Promoter Methylation in Normal Karyotype AML: A Study on 623 Cases
por: Fasan, Annette, et al.
Publicado: (2013)

Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts
por: Huber, Sandra, et al.
Publicado: (2022)

AML classification in the year 2023: How to avoid a Babylonian confusion of languages
por: Huber, Sandra, et al.
Publicado: (2023)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
por: Huber, Sandra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gj9mgeicg26boa46ildr5f2p7f